Relugolix Combination Therapy Improves Hemoglobin Levels in Anemic Women with Uterine Fibroids: Results from the Liberty Phase 3 Program
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Minimally Invasive Gynecology"
DOI: 10.1016/j.jmig.2020.08.315
Abstract: Study Objective To evaluate the effect of Relugolix combination therapy (Rel-CT) on hemoglobin in women with uterine fibroids (UF) and anemia. Design LIBERTY 1 and 2 are phase 3, multinational, randomized, double-blind, placebo-controlled studies. Setting… read more here.
Keywords: relugolix; volume; relugolix combination; uterine fibroids ... See more keywords
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
Sign Up to like & getrecommendations! Published in 2022 at "Obstetrics and Gynecology"
DOI: 10.1097/aog.0000000000004988
Abstract: Relugolix combination therapy showed sustained improvement of uterine leiomyoma–associated symptoms and patient-reported quality of life through 52 weeks. OBJECTIVE: In the LIBERTY 1 and LIBERTY 2 placebo-controlled trials, once-daily relugolix combination therapy reduced menstrual blood… read more here.
Keywords: uterine leiomyoma; relugolix combination; combination therapy;
A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.
Sign Up to like & getrecommendations! Published in 2023 at "Pain management"
DOI: 10.2217/pmt-2022-0085
Abstract: WHAT IS THIS SUMMARY ABOUT? This is a summary of research studies (known as clinical trials) called LIBERTY 1 and LIBERTY 2. The LIBERTY 1 and LIBERTY 2 studies looked at how well a medication… read more here.
Keywords: liberty liberty; relugolix combination; combination therapy;